Pasquale Innominato1, Sandra Komarzynski1, Abdoulaye Karaboué1, Ayhan Ulusakarya1, Mohamed Bouchahda1, Mazen Haydar1, Rachel Bossevot-Desmaris1, Magali Mocquery1, Virginie Plessis1, Francis Lévi1. 1. Pasquale Innominato, North Wales Cancer Centre, Betsi Cadwaladr University Health Board, Denbighshire; Pasquale Innominato, Sandra Komarzynski, and Francis Lévi, Warwick Medical School, Coventry, United Kingdom; Pasquale Innominato, Sandra Komarzynski, Ayhan Ulusakarya, Mohamed Bouchahda, and Francis Lévi, Institut National de la Santé et de la Recherche Médicale, Unit 935; Ayhan Ulusakarya, Mohamed Bouchahda, Mazen Haydar, Rachel Bossevot-Desmaris, Magali Mocquery, Virginie Plessis, and Francis Lévi, Assistance Publique-Hôpitaux de Paris, Paul Brousse Hospital, Villejuif; and Abdoulaye Karaboué, AK-SCIENCE, Research and Therapeutic Innovation, Vitry-sur-Seine, France.
Abstract
PURPOSE: To assess the impact of chronomodulated irinotecan fluorouracil-leucovorin and oxaliplatin (chronoIFLO4) delivered at home on the daily life of patients with cancer in real time using a home-based e-Health multifunction and multiuser platform. This involved multidimensional telemonitoring of circadian rest-activity rhythm (CircAct), sleep, patient-reported outcome measures, and body weight changes (BWCs). PATIENTS AND METHODS: Patients received chronoIFLO4 fortnightly at home. Patients completed the 19-item MD Anderson Symptom Inventory on an interactive electronic screen, weighed themselves on a dedicated scale, and continuously wore a wrist accelerometer for CircAct and sleep monitoring. Daily data were securely teletransmitted to a specific server accessible by the hospital team. The clinically relevant CircAct parameter dichotomy index I < O and sleep efficiency (SE) were calculated. The dynamic patterns over time of patient-reported outcome measures, BWC, I < O, and SE informed the oncology team on tolerance in real time. RESULTS: The platform was installed in the home of 11 patients (48 to 72 years of age; 45% men; 27% with performance status = 0), who were instructed on its use on site. They received 26 cycles and provided 5,891 data points of 8,736 expected (67.4%). The most severe MD Anderson Symptom Inventory scores were: interference with work (mean: 5.1 of 10) or general activity (4.9), fatigue (4.9), distress (4.2), and appetite loss (3.6). Mean BWC was -0.9%, and mean SE remained > 82%. CircAct disruption (I < O ≤ 97.5%) was observed in four (15%) cycles before chronoIFLO4 start and in five (19%) cycles at day 14. CONCLUSION: The patient-centered multidimensional telemonitoring solution implemented here was well accepted by patients receiving multidrug chemotherapy at home. Moreover, it demonstrated that chronoIFLO4 was a safe therapeutic option. Such integrated technology allows the design of innovative management approaches, ultimately improving patients' experience with chemotherapy, wellbeing, and outcomes.
PURPOSE: To assess the impact of chronomodulated irinotecanfluorouracil-leucovorin and oxaliplatin (chronoIFLO4) delivered at home on the daily life of patients with cancer in real time using a home-based e-Health multifunction and multiuser platform. This involved multidimensional telemonitoring of circadian rest-activity rhythm (CircAct), sleep, patient-reported outcome measures, and body weight changes (BWCs). PATIENTS AND METHODS: Patients received chronoIFLO4 fortnightly at home. Patients completed the 19-item MD Anderson Symptom Inventory on an interactive electronic screen, weighed themselves on a dedicated scale, and continuously wore a wrist accelerometer for CircAct and sleep monitoring. Daily data were securely teletransmitted to a specific server accessible by the hospital team. The clinically relevant CircAct parameter dichotomy index I < O and sleep efficiency (SE) were calculated. The dynamic patterns over time of patient-reported outcome measures, BWC, I < O, and SE informed the oncology team on tolerance in real time. RESULTS: The platform was installed in the home of 11 patients (48 to 72 years of age; 45% men; 27% with performance status = 0), who were instructed on its use on site. They received 26 cycles and provided 5,891 data points of 8,736 expected (67.4%). The most severe MD Anderson Symptom Inventory scores were: interference with work (mean: 5.1 of 10) or general activity (4.9), fatigue (4.9), distress (4.2), and appetite loss (3.6). Mean BWC was -0.9%, and mean SE remained > 82%. CircAct disruption (I < O ≤ 97.5%) was observed in four (15%) cycles before chronoIFLO4 start and in five (19%) cycles at day 14. CONCLUSION: The patient-centered multidimensional telemonitoring solution implemented here was well accepted by patients receiving multidrug chemotherapy at home. Moreover, it demonstrated that chronoIFLO4 was a safe therapeutic option. Such integrated technology allows the design of innovative management approaches, ultimately improving patients' experience with chemotherapy, wellbeing, and outcomes.
Authors: Pasquale F Innominato; Annabelle Ballesta; Qi Huang; Christian Focan; Philippe Chollet; Abdoulaye Karaboué; Sylvie Giacchetti; Mohamed Bouchahda; René Adam; Carlo Garufi; Francis A Lévi Journal: Cancer Med Date: 2020-04-22 Impact factor: 4.452
Authors: Youmin Cho; Yun Jiang; Huiting Zhang; Marcelline Ruth Harris; Yang Gong; Ellen Lavoie Smith Journal: J Med Internet Res Date: 2021-03-12 Impact factor: 5.428
Authors: Pasquale F Innominato; Abdoulaye Karaboué; Christian Focan; Philippe Chollet; Sylvie Giacchetti; Mohamed Bouchahda; Ayhan Ulusakarya; Angela Torsello; René Adam; Francis A Lévi; Carlo Garufi Journal: Int J Cancer Date: 2020-12-03 Impact factor: 7.396
Authors: Laleh G Melstrom; Andrei S Rodin; Lorenzo A Rossi; Paul Fu; Yuman Fong; Virginia Sun Journal: J Surg Oncol Date: 2020-09-24 Impact factor: 3.454